• Economy
  • Editor’s Pick
Money Rise Today – Investing and Stock News
  • Investing
  • Stock
Investing

Eli Lilly’s tirzepatide injection results could trigger another bull run: Here’s why

by August 1, 2024
written by August 1, 2024

Eli Lilly and Company (NYSE: LLY) recently announced promising results from its SUMMIT phase 3 trials, focusing on the efficacy of the tirzepatide injection.

The positive findings have sparked investor interest, driving the stock up by 3% today.

These results are not only significant for Eli Lilly but also hold potential for millions of patients suffering from heart failure with preserved ejection fraction (HFpEF) and obesity.

Promising trial results

The SUMMIT phase 3 trial results revealed that tirzepatide reduced the risk of heart failure outcomes by 38% compared to a placebo. Additionally, all key secondary endpoints were successfully met, including:

It reduced the risk of heart failure outcomes by 38% compared to placebo.

All l key secondary endpoints were met successfully. These included exercise capacity, mean body weight reduction from baseline at 52 weeks, and reduction in the inflammation marker high-sensitivity C-reactive protein.

For the efficacy estimand, it led to a 15.7% weight reduction compared to 2.2% for placebo.

For the treatment regimen estimand, it led to a 13.9% reduction in body weight compared to 2.2% for placebo.

Why is this result significant?

The result carries weight because HFpEF (heart failure with preserved ejection fraction) accounts for 50% of all heart failure cases. In the US, 60% of those also suffer from obesity.

It is a condition where the left pumping chamber of the heart becomes stiff and is unable to fill normally. Thanks to tirzepatide, this problem can finally be addressed.

The company will now submit the SUMMIT study findings to the FDA and hope for a positive response from them. If the drug is approved, tirzepatide could become the cornerstone of Eli Lilly’s portfolio and substantially boost revenue.

CEO says shortage of tirzepatide should end soon

CEO David Ricks had more good news for the investors today as he claimed the shortage of tirzepatide should end soon. He made this revelation during an interview with Bloomberg.

Some doses of LLY’s weight loss drugs Zepbound and Mounjaro have been on FDA’s shortage list for some time now. In fact, Mounjaro is on that list since since 2022.

The company had initially stated in April that it expects the supply to remain tight. However, the CEO’s comments have increased investor confidence and hopes.

What does the chart say?

LLY stock has been on a downslide recently as the US market corrects across the board. The announcement of the drug trial comes at a time when the stock was about to test a key support level as shown in the chart below.

The trendline that started over a year ago was about to be approached but the stock price never reached there. Traders will probably still wait for a retesting of that line but investors, on the back of above positive developments will hope that the retesting isn’t needed and the stock can continue its upward journey.

As the market tumbles today, investors will find comfort in the fact that LLY stock is still up 3%. Only time will tell if that’s temporary though.

The post Eli Lilly’s tirzepatide injection results could trigger another bull run: Here’s why appeared first on Invezz

0 comment
0
FacebookTwitterPinterestEmail

previous post
CleanSpark expands in Wyoming, overtakes Riot as second-largest Bitcoin miner in US
next post
Riot Platforms stock has a 71% upside: analyst

related articles

Asian markets open: Nikkei, Hang Seng fall on...

June 12, 2025

Aluminum and steel tariffs spark rise in secondary...

June 12, 2025

Airbus sees aviation boom ahead, global fleet to...

June 12, 2025

US-China trade talks and Washington’s decade-long effort to...

June 12, 2025

Europe markets open: Stoxx 600 dips as UK...

June 12, 2025

UK GDP falls by 0.3% in April as...

June 12, 2025

Gordon Brothers buys Poundland; pledges £80 mn for...

June 12, 2025

Air India plane crash: London-bound flight with 242...

June 12, 2025

Air India plane crash live update: Indian President...

June 12, 2025

Copper remains supported for now even as China...

June 12, 2025
Enter Your Information Below To Receive Free Trading Ideas, Latest News, And Articles.


Your information is secure and your privacy is protected. By opting in you agree to receive emails from us. Remember that you can opt-out any time, we hate spam too!

Latest News

  • ‘Deadpool & Wolverine’ surpasses $1 billion globally; second R-rated film to achieve this milestone

    August 12, 2024
  • GOP lawmakers rebuke Elon Musk’s primary threats, say Trump’s legislation ‘something we’ve got to do’

    July 3, 2025
  • First Solar stock outlook: How a Trump presidency and Inflation Reduction Act will shape its future

    July 24, 2024
  • Biden-appointed federal judge keeps blocking Trump admin from nixing funding for lawyers for migrant children

    April 30, 2025
  • Jill Biden’s ‘work husband’ runs for cover as privilege protection crumbles

    June 26, 2025

Popular Posts

  • 1

    Secret Service admits leaning on ‘state and local partners’ after claim it ignored Trump team’s past requests

    July 21, 2024
  • 2

    Five more House Democrats call on Biden to drop out, third US senator

    July 19, 2024
  • 3

    Elon and Vivek should tackle US funding for this boondoogle organization and score a multimillion dollar win

    December 4, 2024
  • 4

    Forex Profit Calculator: Maximize Your Trading Potential

    July 10, 2024
  • 5

    Biden calls to ‘lower the temperature’ then bashes Trump in NAACP speech

    July 17, 2024

Categories

  • Economy (829)
  • Editor's Pick (6,509)
  • Investing (634)
  • Stock (941)

Latest Posts

  • Comer, Crockett clash over Barr’s Epstein testimony as ex-Trump AG ends four-hour House grilling

    August 18, 2025
  • The Fed may soon cut interest rates. That could make your next trip abroad more expensive.

    July 11, 2024
  • Long US100: anticipating further gains amid strong uptrend, key resistance break, and fed rate outlook

    November 7, 2024

Recent Posts

  • Here’s what happened during Trump’s 11th week in office

    April 5, 2025
  • With 11 days until voting starts, ‘election season’ kicks off sooner than you think

    August 26, 2024
  • Oil and Natural Gas: The price of oil is back above $83.00

    July 12, 2024

Editor’s Pick

  • Jim Jordan subpoenas company led by daughter of NY v Trump judge

    August 28, 2024
  • Kamala Harris to skip Netanyahu’s address to Congress, while top Dem senator boycotts altogether

    July 23, 2024
  • Citadel’s Ken Griffin buys a stegosaurus for $45 million in a record auction sale

    July 19, 2024
  • About us
  • Contacts
  • Privacy Policy
  • Terms & Conditions

Disclaimer: moneyrisetoday.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

Copyright © 2025 moneyrisetoday.com | All Rights Reserved

Money Rise Today – Investing and Stock News
  • Economy
  • Editor’s Pick
Money Rise Today – Investing and Stock News
  • Investing
  • Stock